Current research is focused on understanding the molecular pathways through which DHT influences cancer cell growth. Studies are also exploring the potential of combining 5-alpha-reductase inhibitors with other cancer therapies to enhance treatment efficacy. Researchers are continually seeking to identify biomarkers that can predict an individual's response to DHT-targeting therapies.
